Company to Demonstrate How its Multiplo Rapid Tests can
Maximize Impact, Efficiency and Return on Program
Investments
HALIFAX,
June 10, 2014 /CNW/ - MedMira
Inc. (TSXV: MIR) will showcase its rapid HIV, hepatitis
and syphilis multiplex test to more than 1,500 sexually transmitted
disease (STD) and HIV experts this week at the 2014 STD Prevention Conference in Atlanta, GA. This biennial event, which
concentrates on domestic and international STD prevention
initiatives, gives community organizations, individuals, public
health professionals, clinicians, and advocates the opportunity to
exchange information about effective prevention. The theme for this
year's conference is "More STD Prevention for the Money: Maximizing
Impact, Efficiency and Return on Program Investments."
MedMira's Multiplo™ rapid diagnostics are built
on the Company's patented Rapid Vertical Flow Technology™, which
enables the simultaneously delivery of multiple tests results on a
single test cartridge with one drop of specimen, saving healthcare
providers and their patients time and money. These tests are
extremely advantageous for diagnosing and treating populations at
risk of multiple infections, such as HIV and hepatitis, which share
similar transmission routes and impact treatment outcomes. They
also benefit those whose access to care may be limited, and who may
easily be lost to follow-up.
"Delivering multiple test results in a single
visit is to everyone's advantage in STD prevention. Both the
healthcare provider and the patients can benefit from reduced time
and costs, and quicker access to the right course of treatment,"
said Neeraj Vats, Director of Technology and Business Affairs,
MedMira Inc. "Our technology, and the multiplexing capabilities it
delivers, creates opportunities for program managers and care
providers to expand or combine existing testing programs dedicated
to just one disease to encompass multiple diseases. They can triple
the number of results they deliver without having to triple
resources, testing time, and cost."
MedMira will present results illustrating that
the performance of its rapid, easy-to-use screening/diagnostic
tool, Multiplo Rapid HBc/HIV/HCV Antibody Test, is comparable to
conventional laboratory methods for early detection of disease. The
presentation will also outline how implementing multiplex tests in
STD prevention programs can maximize return on investments
MedMira is currently implementing multicenter
clinical trials for its Multiplo HBc/HIV/HCV test across
the United States. MedMira's
Reveal™ HBsAg rapid test, a new rapid test for hepatitis B surface
antigen, and the Company's most advanced whole blood rapid HIV
test, Reveal G4, are also part of these ongoing clinical trials.
Moreover, MedMira's Multiplo TP/HIV test is currently advancing
through the WHO prequalification of diagnostics process. Together,
these tests give healthcare providers a powerful suite of rapid
tools designed to better inform patients and maximize STD screening
and diagnostic efforts.
About MedMira
MedMira is a leading developer and manufacturer
of vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the Reveal, Multiplo and Miriad™
brands in global markets. Based on its patented Rapid Vertical Flow
Technology, MedMira's rapid HIV test is the only one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.